Power3 Medical Products in Collaboration with StemTroniX, Inc., to Identify and Monitor Autologous Adult Stem Cells for Use in Stem Cell Therapy using Protein Biomarkers

Business Wire, Oct 9, 2008

HOUSTON -- Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), today announced that the company has executed a Letter of Intent with StemTroniX, Inc., a Texas based Stem Cell Therapy Company that specializes in research, exploration and consolidation of stem cell technologies for use in Autologous Adult Stem Cell Therapy's and Transplantations.

"Power3 Medical is excited about this collaboration," commented Dr. Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. "With our recently published patent application on human bone marrow stem cell protein biomarkers for drug resistance in leukemia patients, the usefulness of our biomarker discovery technology for stem cell therapy applications has already been demonstrated. We are confident that this new effort with StemTroniX will not only add to our pipeline of protein biomarkers and tests for breast cancer, neurodegenerative diseases and other markets, but will also provide an inroad into companion diagnostics for treatment of these and other diseases."

"The collaboration with Power3 Medical we will leverage our synergistic proprietary technologies," stated Helen R. Park, Interim C.E.O. for Power3 and Founder and Director of StemTroniX, Inc. "StemTroniX feels that we will achieve significant breakthroughs in specific stem cell therapies by employing specific protein biomarkers discovered with Power3 to identify specific stem cells for treatment. We think we are on the right track."

About Power3 Medical Products, Inc.:

Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.

About StemTroniX, Inc.:

StemTroniX is a private expansion stage holding company that specializes in autologous adult blood stem cell technologies that are effectively used in stem cell therapy and transplantation to enhance organ and tissue regeneration. As previously announced, StemTroniX, Inc. intends to become a publicly traded company through a reverse merger with WGL Entertainment Holdings, Inc. (OTCPK:WEHI).

Forward Looking Statement

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

For more information regarding Power3 Medical, contact:

Helen R. Park, M.S.
Interim CEO
3400 B-2 3 Research Forest Dr.
The Woodlands, TX 77381
(281) 464-1600
FAX: (281) 466-1481
hpark@power3medical.com
www.power3medical.com

For more information regarding WGL Entertainment Holdings, contact:

Investor Relations
1-866-THE-APPL(E)

http://www.wglmilliondollarshootout.com